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In Germany  strong  efforts  have  been  made  within  the  last  years  to develop  new  methods  for  human
biomonitoring  (HBM).  The  German  Federal  Ministry  for  the Environment,  Nature  Conservation,  Building
and  Nuclear  Safety  (BMUB)  and the German  Chemical  Industry  Association  e. V.  (VCI)  cooperate  since
2010  to increase  the  knowledge  on the  internal  exposure  of  the  general  population  to  chemicals.  The
projects  aim  is  to promote  human  biomonitoring  by developing  new  analytical  methods  Key  partner  of
the cooperation  is  the  German  Environment  Agency  (UBA)  which  has  been  entrusted  with  the  scientiﬁc
coordination.  Another  key  partner  is  the  “HBM  Expert  Panel”  which  each  year  puts  together  a list  of
chemicals  of  interest  to the project  from  which  the  Steering  Committee  of  the  project  choses  up  to ﬁve
substances  for which  method  development  will  be  started.  Emphasis  is placed  on  substances  with  either
a  potential  health  relevance  or on  substances  to which  the general  population  is potentially  exposed  to
a considerable  extent.
The  HBM  Expert Panel  also  advises  on  method  development.  Once  a method  is  developed,  it  is  usually
ﬁrst  applied  to about  40 non-occupationally  exposed  individuals.  A  next  step is applying  the  methods  to
different  samples.  Either,  if the  time  trend  is  of  major  interest,  to samples  from  the German  Environmental
Specimen  Bank,  or,  in case  exposure  sources  and  distribution  of exposure  levels  in the  general  population
are  the  focus,  the  new  methods  are  applied  to  samples  from  children  and  adolescents  from  the  population
representative  5th German  Environmental  Survey  (GerES  V).  Results  are  expected  in  late 2018.
This article  describes  the  challenges  faced  during  method  development  and  solutions  found.  An
overview  presents  the  34 selected  substances,  the 14 methods  developed  and the  7  HBM-I  values  derived
in the  period  from  2010  to mid  2016.
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. Introduction and background
The exposure of the German population to chemicals is substan-
ially related to the use and production of chemicals, to products
nd consumer goods, to the contamination of food as well as
odayı´s living conditions. Their safety for human beings and the
nvironment has to be safeguarded by producers and the gov-
rnment. One important tool for identifying exposure levels and
ources, informing policy decisions and evaluating the success of
isk reduction strategies is human biomonitoring (HBM) (Angerer,
012; Kolossa-Gehring et al., 2012). HBM is the most appropriate
cientiﬁc technique for assessing human exposure to environmen-
al pollutants based usually on sampling and analysis of blood
r urine. By linking the biomonitoring results with environmen-
al and health data or by a toxicologically/epidemiologically based
ssessment of the exposure levels HBM can build bridges between
xposure to pollutants and health effects and can give indication
or appropriate public health measures. Time trends of exposure
nd different exposure levels of sub-groups of the population can
lso be detected (Schulz et al., 2007a,b).
Exposures of concern, such as to heavy metals like lead, to per-
istent organic pollutants like PCB and DDT, to PAHs taken up from
utdoor air pollution and to phthalates used e. g. as plasticizers
ave been efﬁciently reduced by the introduction of risk reduc-
ion measures like restriction in use or complete bans of chemicals.
owever, banned or restricted chemicals are often substituted by
ubstances for which no data on internal exposure and/or no toxico-
ogically derived guidance values for an assessment of their health
elevance are available. Without data it is not possible to distin-
uish between recommendable and problematic substitutes or to
ive advice to the general population on how to efﬁciently reduce
n impact on health from the exposure to chemicals (Zota et al.,
014; Schütze et al., 2014; Göen et al., 2011). HBM should thus also
e used to investigate substitutes.
In the past HBM methods have primarily been developed for
hemicals relevant at the workplace. Later on, a set of methods
or heavy metals, persistent compounds, biocides and industrial
hemicals relevant for the general population has been established.
ost of the HBM studies worldwide measure a similar set of chem-
cals today (Kolossa-Gehring, 2012). In many cases the awareness
f exposure and the subsequent development of appropriate risk
eduction measures led to a reduction of exposure. Subsequent
tudies observed and followed up these reductions.
In Germany, a cooperation was set up in 2010 to broaden the
oolbox of HBM methods and thus enhance the use of HBM for
olicy making. The German Ministry for the Environment, Nature
onservation, Building and Nuclear safety (BMUB) and the Ger-
an  Chemical Industry Association (VCI), supported by the German
nvironment Agency (UBA) and an “HBM Expert Panel”, identify
hemicals with potential consumer exposure and potential health
elevance for the general population which up to now cannot be
reliably) measured by HBM. Each year up to ﬁve chemicals are cho-
en for the development of new HBM methods (Kolossa-Gehring
t al., 2012; Kolossa-Gehring 2012).
The VCI has taken on the responsibility of developing the new
etection methods. While advised by the HBM Expert Panel, it is
he task of the VCI to commission an analytical laboratory which it
onsiders suitable for developing a valid analytical method.
Applying the methods in suitable studies and interpreting their
esults is the responsibility of the BMUB in close cooperation with
he UBA. Thus there is a clear division of responsibilities which is a
ore feature of the project.Please cite this article in press as: Kolossa-Gehring, M.,  et al., New hum
approach to enhance relevance. Int. J. Hyg. Environ. Health (2016), htt
Reliable exposure data alone, however, does not allow to evalu-
te the health relevance of a given level of exposure. That evaluation
s performed outside of the cooperation project. It is performed
y the German Human Biomonitoring Commission (Schulz et al., PRESS
ne and Environmental Health xxx (2016) xxx–xxx
2007b; Angerer et al., 2011; Apel et al., 2016) which derives HBM
values from toxicological data. The HBM Commission was estab-
lished in 1992 and has the mandate to support the UBA by giving
advice concerning HBM related issues and health-related environ-
mental monitoring. The Commission members are appointed by the
President of the UBA. They are independent scientists and experts
from authorities at the Federal and Bundesländer (Federal States)
level, universities, public health institutes and clinical institutes.
In the following, the operation (modus operandi) and the
achievements reached so far by the BMUB/VCI cooperation are
described.
2. Methods
2.1. Identiﬁcation of chemicals of relevance
The HBM Expert Panel consists of experts from the Federal Ger-
man  scientiﬁc agencies in charge of chemicals regulation, that is the
Federal Institute for Risk Assessment (BfR), the Federal Institute for
Occupational Safety and Health (BAuA) and the UBA as well as of
experts from chemical industry enterprises and from universities
and other scientiﬁc institutions. This panel provides advice on the
selection of substances and the development of methods.
A steering committee composed of representatives of the BMUB,
the UBA, the VCI and VCI member companies decides each year for
which substances new methods are to be developed.
The idea for the project was  created in 2009 in a joint BMUB/VCI
meeting on HBM. An agreement was negotiated and the project
then started in 2010. To get the work of the HBM Expert Panel
started, a list of chemicals of interest was  put together by the BfR,
the BAuA and the UBA. It was  based on at that time available lists
of nationally and internationally relevant substances already com-
piled by other experts. The ﬁrst focus was laid on the REACH-Annex
XIV-candidate list and the list of PBT/vPvB- substances. For the
following year a list of 120 substances of interest was  set up.
Table 1 gives an overview about the most relevant substance
lists which were considered. Additionally the scientiﬁc Federal
Agencies identiﬁed chemicals of interest from their respective
ﬁelds of competence which had raised concern or were under dis-
cussion in science or in the public. Representatives from industry
also proposed additional chemicals for method development.
The above mentioned list is regularly reviewed in the course
of the cooperation and supplemented as needed. Any expert, or
institution, participating in the HBM Expert Panel, can suggest new
substances. It is, however, required that any suggestion for a new
substance is accompanied by a fact sheet with i.a. toxicological
information.
In that list the substances are classiﬁed in 13 groups: 1)
Phthalates and substitutes; 2) Flame retardants; 3) Per-and
polyﬂuorinated alkyl substances (PFAS); 4) Chemicals used in
cosmetics; 5) (Musk) fragrances; 6) Allergenic substances; 7)
(Phenol-)Benzothiazoles; 8) SVHC candidates (REACH Art. 57); 9)
Aromatic amines; 10) Metals; 11) Nano particles; 12) Contami-
nants in food; 13) Others. Substance attribution to a group follows
either its chemical constitution or use (e.g. Phthalates, including
other plasticizers) or its potential health effect (Allergenic sub-
stances) depending on the main characteristics. The basic criteria
for selection of substances besides their toxicology are their good
or very good bioavailability (health relevance), a high likelihood
of consumer exposure (consumer relevance) and non-existence or
unsuitability of an existing HBM-method (for mother compound oran biomonitoring methods for chemicals of concern—the German
p://dx.doi.org/10.1016/j.ijheh.2016.10.012
metabolites).
Once a year, following a scientiﬁc discussion, the HBM Expert
Panel releases a short list of proposed substances with sufﬁcient
data available to classify them as eligible for the cooperation
ARTICLE IN PRESSG ModelIJHEH-13002; No. of Pages 10
M. Kolossa-Gehring et al. / International Journal of Hygiene and Environmental Health xxx (2016) xxx–xxx 3
Table  1
Substance lists considered for the start of the BMUB/VCI cooperation in 2009.
List of carcinogenic, mutagenic, reprotoxic (CMR) substances (as from January
2009)a
REACH-Annex XIV-candidate listb (as from March 2009)
List of PBT/vPvB- substancesc (67/548/EECd and 793/93/EECe as from May
2008):127 substances
SVHC-candidate listf (34 substances, as from March 2009)
ICCAg HPV-list (International Council Chemical Associations, as from October
2005)
OECD-HPV-Listh (as from 2004)
EDS-List (List of endocrine disrupting substance, Annex 1 of the EU-strategy) i
NORMAN-List of “Emerging Substances”j (as from March 2009)
NHANES-substancesk (National Health and Nutrition Examination Survey, USA)
HESIl-List (bioaccumulation, Health and Environmental Science Institute, USA).
a Regulation (EC) No 1272/2008 of the European Parliament and of the Coun-
cil  of 16 December 2008 on classiﬁcation, labelling and packaging of substances
and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and
amending Regulation (EC) No 1907/2006 (Text with EEA relevance) http://eur-lex.
europa.eu/eli/reg/2008/1272/oj.
b echa.europa.eu/documents/10162/13585/pr 09 01 consultation substances
authorisation 20090114 en.pdf.
c The TC NES sub-group on identiﬁcation of PBT and vPvB substances
assessed suspected PBTs (persistent, bioaccumulative and toxic) and vPvBs (very
persistent and very bioaccumulative) under the previous EU chemicals leg-
islation. https://echa.europa.eu/information-on-chemicals/pbt-vpvb-assessments-
under-the-previous-eu-chemicals-legislation.
d Council Directive 67/548/EEC of 27 June 1967 on the approximation of laws,
regulations and administrative provisions relating to the classiﬁcation, packaging
and labeling of dangerous substances.
e EC (European Commission), 1993. Council Regulation 793/93/EEC of March 1993
on  the evaluation and control of risks of existing substances. Ofﬁcial Journal of the
European Communities, L48/1.
f https://echa.europa.eu/candidate-list-table.
g https://www.icca-chem.org/.
h www.oecd.org/chemicalsafety/risk-assessment/33883530.pdf.
i Candidate list of 553 substances ec.europa.eu/environment/archives/docum/
pdf/bkh annex 01.pdf.
j http://www.norman-network.net/?q=node/81.
k Chemicals measured in selected participants for NHANES 2003–2004: http://
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Table 2
Characteristics of substances which hamper their use as a valid biomarker.
Substance characteristic Disadvantage
Ubiquitously present in the
environment
Possibility of exogenous contamination
(may lead to overestimation of
exposure)
Formed naturally in the body and
excreted in high concentrations
No distinction between internal body
dose and external supply possible (may
lead to overestimation of exposure)
Rapidly metabolized or eliminated
in humans (short half-live)
Can easily result in an underestimation
of exposure
Formed or excreted in very small Can easily result in an underestimationiomonitoring.ca.gov/downloads/chemicals-measured-selected-participants-
hanes-2003-2004-0.
l http://hesiglobal.org/.
roject. Then, the Steering Committee selects up to 5 substances
or that year for which HBM method development will be started.
hen deciding on the substances of choice, consideration is given
o whether the VCI is able to ﬁnd industrial sponsors for the sub-
tance whose expertise is required for the effective development
f analytical methods. Therefore, it turned out to facilitate the pro-
edures if the producer of a chosen chemical is located in Germany.
ith the project running for 10 years, up to 50 substances shall
hus be selected until 2020.
.2. Biomarker identiﬁcation
The agreement between the BMUB and the VCI puts empha-
is on developing a “valid method” in order to be able to properly
ssess exposure levels. In the course of the project and discussion in
he HBM Expert Panel, the conditions for an appropriate approach
or method developing were established. One condition relates
o the contracted laboratories: it is recommended that contracts
or method development should only be awarded to laboratories
hich have sufﬁcient experience in human biomonitoring. It is
f advantage if the laboratories are routinely involved in human
iomonitoring and do scientiﬁc work in this ﬁeld.
Another condition relates to the biomarkers: The HBM Expert
anel agreed that the key challenge in method development is toPlease cite this article in press as: Kolossa-Gehring, M.,  et al., New hum
approach to enhance relevance. Int. J. Hyg. Environ. Health (2016), htt
hoose the right biomarker. Table 2 lists substance characteristics
hich are contradictory to a qualiﬁcation as a biomarker.
The use of an ill-suited biomarker may  result in over- or under-
stimation of the exposure (Table 2). This can be circumvented if theamounts of exposure
Metabolite of several substances Speciﬁcity is insufﬁcient (may lead to
overestimation of exposure)
human metabolism of the substance of concern is disclosed. Only
the appropriate biomarker (which might also be the mother sub-
stance) provides a promising starting point for the development
of an analytical method. To ﬁnd this appropriate biomarker, i. e.
that metabolite which reliably reﬂects internal human exposure to
the substance in question, different actions are to be undertaken
depending on the level of knowledge about the metabolism.
Each substance in question needs a separate, profound evalu-
ation on the necessity to perform a short or extended study on
human metabolism depending on the existing knowledge. Table 3
lists main aspects to consider for the decision of the necessity of
a human metabolism study and examples within the BMUB/VCI
cooperation. Five levels of knowledge can be distinguished pro-
voking different actions.
The bigger the knowledge on human metabolism, the less com-
plex is the preliminary work for method development.
Studies on human metabolism are also needed to derive toxi-
cology based guidance values like the HBM values of the German
Human Biomonitoring Commission. Each human metabolism study
has to have an authorization of an ethics commission.
2.3. Method development
After VCI has subcontracted a laboratory for method devel-
opment, the work can start. Besides the above mentioned
recommendations for ﬁnding the appropriate biomarker, each
method development should obey the following stipulations:
1) The method should preferably be developed for urine (non-
invasive matrix) to facilitate the use in studies on children.
Collection in conventional plastic vessels should be possible.
2) The methods will afterwards be applied to large population stud-
ies, therefore the method should run in fast routine on devices
which are regularly found in human biomonitoring laboratories.
The method should, if possible, not be cost-intensive.
3) A low limit of quantiﬁcation (LOQ) is necessary, suitable for
environmental exposure of the general population, including
children and adolescents. The LOQ must be well below the LOQ
for occupational exposure, preferably be as low as 1 g/l or less.
In general, a concentration of 0,1 g/l urine or plasma should be
achieved.
4) Applying the new method to 30–40 occupationally non-exposed
participants is also part of the method development.
Fig. 1 provides a ﬂow chart about the method development.
Regularly, the ﬁrst step of the method development is the syn-
thesis of the analytical standards (substance which is supposed toan biomonitoring methods for chemicals of concern—the German
p://dx.doi.org/10.1016/j.ijheh.2016.10.012
be the marker) and the internal standards (e.g. 13C or deuterium
labeled standard). During the course of the cooperation project the
development of these standard synthesis has shown to be some-
times a time consuming factor.
Please cite this article in press as: Kolossa-Gehring, M.,  et al., New human biomonitoring methods for chemicals of concern—the German
approach to enhance relevance. Int. J. Hyg. Environ. Health (2016), http://dx.doi.org/10.1016/j.ijheh.2016.10.012
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Fig. 1. The ﬂow chart shows the different steps of the development of an analytical method within the BMUB/VCI cooperation and depicts the involvement of the various
parties.
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Table  3
Necessity of a human metabolism study for detection of an appropriate biomarker.
Knowledge level Biomarker Human metabolism study Finalization of method
development
Examples (full names see
Table 4)
1: Human metabolism known
or results of animal studies
can be used
identiﬁed Not necessary Directly possible HBCDD, 4-MBC
2:  Metabolism of substances
with a similar structure are
known (can be supported by
results of in vitro studies)
a relevant biomarker can be
assumed on the basis of these
ﬁndings
Recommended to validate the
assumed biomarker
Possible after supporting
metabolism studies
DPHP, DEHTP (analogue to
DEHP); DEHTP: also rested on
in vitro studies;
NEP (analogue to NMP)
3:  Knowledge on human
metabolism fragmentary or
lacking (without possibility
to derive such ﬁndings)
Not known; development can
be complex, time-consuming
and costly
Necessary Only possible after metabolism
is disclosed
CIT/MIT (3:1);
4-tert-Nonylphenol branched;
ASE/ASEP
4:  No studies on human
metabolism exist
(carcinogenic, mutagenic or
reproduction-toxic
substances)
Possibly derived from in vitro
or animal studies data
Not allowed! Targeted
administration of such
substances is prohibited in
humans.
Population background
exposure as basis for
metabolism extrapolations
TDCP
5:  Knowledge on metabolism
impeded due to complexity
Biomarkers from
environmental monitoring
Maybe necessary after
complexity could be solved
Identiﬁcation of a suitable
biomarker still requires major
Chloroparafﬁns: consist of over
10,000 individual compounds,
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(multi-component isomer
mixtures)
may  not be suitable
Important steps and occurring problems during method devel-
pment are addressed at the semiannual meetings of the HBM
xpert Panel.
As part of the method validation, the procedure is cross-
xamined by a second laboratory from the ranks of the scientiﬁc
orking group “Analysis in Biological Materials” of the “Perma-
ent Senate Commission for the Investigation of Health Hazards of
hemical Compounds in the Work Area” of the German Research
oundation (DFG). The method including the examination results
ill be published online by the DFG in open access. This proce-
ure turned out to be another time consuming factor. Therefore, a
ethod is referred to as “ﬁnalized” after a scientiﬁc paper has been
ublished in a peer-reviewed journal.
.4. Substances selected and methods developed
From 2010 to 2016 the Steering Committee of the cooperation
as selected 34 substances for method development. While aiming
t 5 chemicals per year, in 2015 only four substances have been
elected (Table 4, also shows all full substance names). Eight of
he selected substances are phthalates and their substitutes (Group
). Two substances are ﬂame retardants (Group 2); ten substances
re chemicals used in cosmetics (Group 4); ﬁve substances belong
o Group 6 (allergenic substances), three substances to Group 7
(Phenol-)Benzothiazoles) and six substances are summarized into
roup 13 (Others).
The chemicals selected thus belong to ﬁve of the 13 groups
rom the priority substance list. Substances of other groups have
een discussed in the HBM Expert Panel but not proposed to the
teering Committee e.g. because of unclear consumer exposure,
ery short half-lives (selected PFAS), already existing HBM methods
Limonene or environmental phenols like Triclosan or Parabenes),
r because method development for selected structural analogues
hall be bided (Homosalate, UV-327, OIT and BIT). Other substances
roposed by the HBM Expert Panel have not yet been selected by
he Steering Committee mostly because it is difﬁcult to oblige an
ndustrial sponsor especially for substances not produced or traded
n Germany (musk fragrances, some ﬂame retardants).Please cite this article in press as: Kolossa-Gehring, M.,  et al., New hum
approach to enhance relevance. Int. J. Hyg. Environ. Health (2016), htt
Table 4 gives an overview of the substances selected and meth-
ds developed so far. Up to now a total of 14 new methods has been
eveloped. Six of them have been published in peer-reviewed jour-
als (HexamollTMDINCHTM, DPHP, DEHTP, MDI, 2-MBT, Lysmeral).research difﬁcult to separate
All ﬁve substances selected in 2010 have successfully passed
the validation process of the DFG (HexamollTMDINCHTM, DPHP,
HBCDD, branched 4-Nonylphenol and 4-tert-Octylphenol). The
method developed for the simultaneous analysis of two  alkylphe-
nols (Nonyl- and Octylphenol) has the disadvantage that
preferentially glass vessels have to be used for urine collec-
tion to achieve a low LOQ (mother substance is subject to
contamination as alkylphenols occur ubiquitously). This is not man-
ageable in routine HBM-studies. First application results in 40
not-occupationally exposed persons with 4-NP did not show any
detectable amount. Additionally, the HBM-Commission of UBA had
doubts that the mother substance is an appropriate biomarker for
4-tert-Nonylphenol and favoured a human metabolism study to
search for other markers, i.e. metabolites to be detected in urine.
The metabolism study is ongoing – here the mother substance as
well as postulated metabolites are measured. The results will clar-
ify the best suitable marker and will be published peer reviewed.
The correct marker can then be applied to human samples.
Method development for all substances selected in 2011 has
been completed.
One substance selected in 2012 has gone through the develop-
ment process, one other is still on its way. Method development
of three substances selected in 2012 did not lead to an acceptable
result. Even though signiﬁcant effort was spent, it was not possible
to develop an appropriate and sufﬁciently sensitive HBM method
for the simultaneous detection of Octamethylcyclotetrasiloxan,
D4 (CAS 556-67-2), Decamethylcyclopentasiloxan, D5 (CAS 541-
02-6) and Dodecamethylcyclohexasiloxan, D6 (CAS 540-97-6) in
urine. Method development failed because these cyclo-siloxanes
are metabolized to the same metabolite (dimethyl-siloxane), so
no separation between these three cyclo-siloxanes would be
possible which is important for taking substance speciﬁc mea-
sures (e.g. regulation). Additionally there is a high background
contamination with dimethyl-siloxane which exacerbates analyt-
ical and pre-analytical procedures (risk of contamination), and
the attainable limit of detection would be 10 fold higher than
intended by the HBM Expert Panel. Thus, method development was
stopped.
3 out of 5 methods for substances selected in 2013 have beenan biomonitoring methods for chemicals of concern—the German
p://dx.doi.org/10.1016/j.ijheh.2016.10.012
developed, and 1 out of 5 for substances selected in 2014. Method
development for the substances selected in 2015 and 2016 is in
process or has just begun.
Please
 cite
 th
is
 article
 in
 p
ress
 as:
 K
olossa-G
eh
rin
g,
 M
.,
 et
 al.,
 N
ew
 h
u
m
an
 biom
on
itorin
g
 m
eth
od
s
 for
 ch
em
icals
 of
 con
cern
—
th
e
 G
erm
an
ap
p
roach
 to
 en
h
an
ce
 relevan
ce.
 In
t.
 J.
 H
yg.
 En
viron
.
 H
ealth
 (2016),
 h
ttp
://d
x.d
oi.org/10.1016/j.ijh
eh
.2016.10.012
A
RTICLE IN PRESS
G
 M
odel
IJH
EH
-13002;
 
N
o.
 of
 Pages
 10
6
 
M
.
 K
olossa-G
ehring
 et
 al.
 /
 International
 Journal
 of
 H
ygiene
 and
 Environm
ental
 H
ealth
 xxx
 (2016)
 xxx–xxx
Table 4
BMUB/VCI-Cooperation: Prioritized chemicals and developed HBM methods 2010–2016 .
Year of selection Name (CAS-No.) Use Method development Biomarker Volume
Matrix
Method; Limit of
Quantiﬁcation (LOQ)
2010 DINCH
1,2-Cyclohexane
dicarboxylic acid
diisononyl ester
(166412-78-8 Isomere
mixture)
Plasticizer: phthalate
substitute in toys, packing
material for food, medical
devices
Completed, published.
Validation by the German
Research Foundation (DFG)
is  completed.
OH-MINCH,
cx-MINCH,
oxo-MINCH
0,3 mL  Urine HPLC–MS/MS
LOQ: all 0,05 g/l
DPHP
Di(2-
propylheptyl)phthalate
(53306-54-0)
Plasticizer: technologically
replaces the phthalate
DIDP in PVC-products for
technical applications
Completed, published.
Validation by DFG is in
process.
oxo-MPHP (1),
OH-MPHP (2),
cx-MPHxP (3)
1,0 mL  Urine GC/HRMS
LOQ: (1) 0,25 g/l;
LOQ: (2) 0,3 g/l;
LOQ:(3) 0,15 g/l
HBCDD
Hexabromocyclododecane
(25637-99-4)
Flame  retardant Completed. Validation by
DFG is completed.
-HBCDD;
ß-HBCDD;
-HBCDD
1,0 mL  Plasma LC–MS/MS
LOQ:
all 0,1 g/l
4-Nonylphenol, branched
(84852-15-3)
Starting material for the
synthesis of nonylphenol
ethoxylates, monomer for
phenolic resins.
Antioxidant/Stabilizer in
technical oils
Completed. Validation by
DFG is completed.
4-Nonylphenol, branched.
A metabolism study is
being performed for
validation
0,5 mL  Urine
One shot for
both
substances
HPLC–MS/MS
LOQ:
all 1,0 g/l
4-tert-Octylphenol
(140-66-9)
Intermediate for the
preparation of synthetic
resins (used for rubber
production for tyres) and
non-ionic surfactants
Completed. Validation by
DFG is completed.
4-tert-Octylphenol
2011 4-MBC
3-(4-Methylbenzyliden)-
camphor
(36861-47-9)
UV-ﬁlter for cosmetics Completed. Submission to
DFG in 2016.
MBC-cx
(3-(4-Carboxy-
benzylidene) camphor)
and
MBC-OH
(3-(4-Carboxy-
benzylidene)-6-
hydroxycamphor)
0,5 mL  Urine HPLC–MS/MS
MBC-cx:
LOQ: 1,5 g/l
MBC-OH:
LOQ: 1,0 g/l
MDI
Methylenediphenyl-
diisocyanate
(101-68-8 and
26447-40-5)
Insulating foam Completed, published.
Validation by DFG is in
process.
5-isopropyl-3-[4-(4-
aminobenzyl)phenyl]hydantoin
ABP-Val-Hyd (Hemoglobin
adduct)
5  mL  EDTA-stabilized
whole blood
GC-HRMS-NCI
LOQ:
0,05 ng ABP-Val-Hyd/g
Globin
2-MBT
(2-Mercaptobenzothiazole)
(149-30-4)
Vulcanization accelerator Completed, published.
Validation by DFG is
completed.
2-MBT 0,5 mL  Urine HPLC–MS/MS
LOQ: 1,0 g/l
NMP
N-Methyl-2-pyrrolidone
(872-50-4)
Solvent in many technical
applications, ingredient in
paint, grafﬁti remover and
carpeting
Completed. Validation by
DFG is in process.
5-Hydroxy-N-Methyl-2-
pyrrolidone
(5-HNMP),
2-Hydroxy-N-methyl-
succiminide
(2-HMSI)
1,0 mL
One shot for
NMP  and NEP
analysis
GC-EI-MS/MS
LOQ:
all 2,5 g/l
NEP
N-Ethyl-2-pyrrolidone
(2687-91-4)
Polar  aprotic solvent,
substitute for NMP, e. g. for
surface coatings, in
cleaning agents and paint
strippers
Completed. Validation by
DFG is in process.
5-Hydroxy-N-
Ethylpyrrolidone (5-HNEP),
2-Hydroxy-N-
ethylsuccinimide
(2-HESI)
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Table 4 (Continued)
Year of selection Name (CAS-No.) Use Method development Biomarker Volume
Matrix
Method; Limit of
Quantiﬁcation (LOQ)
2012 CIT/MIT (3:1)
5-Chloro-2-methyl-4-
isothiazolin-3-one/2-
Methylisothiazol-3(2H)-
one
(55965-84-9)
Preserving additive in
cosmetics and industrial
products, biocides
Completed. Validation by
DFG is in process.
NMMA
Geraniol
(106-24-1)
Fragrance In process.
D4
Octamethylcyclotetrasiloxane
(556-67-2)
Ingredient in
cosmetics
Method
development
for urine not
possible;
ﬁnished
without
success.
D  5
Decamethylcyclopentasiloxane
(541-02-6)
D 6
Dodecamethylcyclohexa-
siloxane
(540-97-6)
2013 ASE/ASEP, Mesamoll®
C10-C20 Alkylsulfonic acid
phenylester
(91082-17-6)
Plasticizer In process.
TOTM
Tri(2-
ethylhexyl)trimellitate
(3319-31-1)
Plasticizer In process.
DEHTP
Di(2-
ethylhexyl)terephthalate
(DEHT, DOTP)
(6422-86-2)
Plasticizer Completed, published.
Validation by DFG is in
process.
5cx-MEPTP (1),
5OH-MEHTP (2),
2cx-MMHTP (3),
5oxo-MEHTP (4)
0,3 mL  Urine HPLC–MS/MS
LOQ (1): 0,2 L
LOQ (2): 0,3 L
LOQ (3): 0,4 L
LOQ (4): 0,2 L
OMC
Octylmethoxycinnamate
(5466-77-3)
UV-ﬁlter for cosmetics In process.
BHT
Butylated Hydroxy Toluene
2,6-Di-tert-butyl-p-cresol
(128-37-0)
Antioxidant e.g. in food Completed. Validation by
DFG is in process.
BHT acid LC–MS/MS
LOQ: 0,1 L
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Table 4 (Continued)
Year of selection Name (CAS-No.) Use Method development Biomarker Volume
Matrix
Method; Limit of
Quantiﬁcation (LOQ)
2014 DINA, Diisononyladipate
(33703-08-1)
Plasticizer In process.
DEHA
Di-(2-ethylhexyl)adipate
103-23-1
Plasticizer In process.
OC,  Octocrylene
(2-Ethylhexyl 2-cyano-3,3-
diphenyl-2-propenoate)
(6197-30-4)
UV-ﬁlter for cosmetics In process.
TDI
Tolylene-diisocyanate
2,4-TDI (584-84-9) and
2,6-TDI (91-08-7)
Foam and adhesives In process.
Lysmeral
2-(4-tert-Butylbenzyl)
propionaldehyde
(80-54-6)
Fragrance Completed, published.
Validation by DFG is in
process.
TBBA (tert-butylbenzoic
acid) (1), Lysmerylic acid
(2),
Lysmerol (3),
OH-Lysmerylic acid (4)
1,0 mL  Urine LC–MS/MS
LOQ (1): 0,42 g/l;
LOQ (2): 0,36 g/l
LOQ (3): 0,10 g/l
LOQ (4): 0,45 g/l
2015 EHS
2-Ethylhexylsalicylate
(Octisalate) (118-60-5)
UV-ﬁlter for cosmetics In process.
Climbazole
1-(4-Chlorophenoxy)-1-
(imidazol-1-yl)3,3-
dimethylbutan-2-one)
(38083-17-9)
Cosmetics preservative
UV 328
P
2-(2H-Benzotriazol-2-yl)-
4,6-di-tert.pentylphenol
(25973-55-1)
UV-absorber for plastics
and paints
7-Hydroxycitronellal
(107-75-5)
Fragrance
2016 TDCP
Tris(1,3-dichloroisopropyl)
phosphate
(13674-87-8)
Flame retardant Method
development
needs at least
two years.
Avobenzone (BMDBM)
Butylmethoxydibenzoyl
methane
(70356-09-1)
UV-ﬁlter in cosmetics
Keromet MD
,‘-(1-methylethylene
diimino)di-o-cresole
(94-91-7)
Fuel additive
DBA, Dibutyl adipate
(105-99-7)
Plasticizer, Ingredient of
cosmetics
Uvinul A Plus
Hexyl 2-(1-(diethylamino
hydrox-
yphenyl)methanoyl)
benzoate
(302776-68-7)
UV-ﬁlter in cosmetics
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Table  5
Human-Biomonitoring (HBM) values for blood and/or urine.
Analyte and sample material Population groups HBM I value HBM II value
Sum of Hexamoll®DINCH® metabolites
OH-MINCH and cx-MINCH in urine [2015]
Children
Adults
3,0 mg/l
4,5 mg/l
/
Sum  of DPHP metabolites
OH-MPHP and oxo-MPHP in urine [2015]
Children
Adults
1,0 mg/l
1,5 mg/l
/
Hexabromcyclododecane (HBCDD) [2015] General population 0,3 g/g lipid or
1,6 g/l blood
plasma
/
2-Mercaptobenzothiazole (2-MBT) in urine [2015] Children
Adults
4,5 mg/l
7,0 mg/l
/
Sum  of N-Methyl-2-pyrrolidone (NMP)-metabolites
5-Hydroxy-NMP and 2-Hydroxy-N-methylsuccinimid
in urine [2015]
Children
Adults
10 mg/l
15 mg/l
30 mg/l
50 mg/l
Sum  of N-Ethyl-2-pyrrolidone (NEP)- metabolites Children
s
10 mg/l 25 mg/l
ren
s
s
m
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f
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s
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j
i
a5-HNEP und 2-HESI in urine [2015] Adult
4-MBC metabolites 3–4CBC and 3–4CBHC
in urine [2016]
Child
Adult
This overview shows that method development is a time con-
uming process. Minimum time is two years from selection to
ethod ﬁnalizing (without publishing) but this is only possible if
iomarker identiﬁcation and biomarker standard synthesis don’t
ace problems.
.5. HBM values derived
The Human Biomonitoring Commission of the UBA derives
oxicologically based HBM values to interpret the relevance
f the exposure levels observed. Up to now HBM values
or seven substances of this cooperation have been derived
HexamollTMDINCHTM, DPHP, NMP, NEP, HBCDD, 2-MBT, 4-MBC)
Table 5). For CIT/MIT (3:1), Geraniol, DEHTP and Lysmeral discus-
ions are ongoing or in preparation. Derivation of HBM value for
DI  failed because of missing metabolism data and the discussion
or HBM values for 4-tert-Nonylphenol and tert-Octylphenol will
o on after the metabolism study is ﬁnalized.
HBM values are regularly updated on the website of the
BM-Commission: https://www.umweltbundesamt.de/en/topics/
ealth/commissions-working-groups/human-biomonitoring-
ommission-hbm-commission.
.6. HBM instruments
On behalf of BMUB, the UBA employs two complementary HBM
ools – the German Environmental Survey (GerES) and the German
nvironmental Specimen Bank (ESB). The new methods, developed
ithin the cooperation to enhance HBM are applied to samples of
hese studies.
GerES is a nationwide representative population study on
uman and indoor air exposure and its sources which has repeat-
dly been carried out in Germany since the mid-1980s. The three
ain instruments of investigation are human biomonitoring in
ombination with indoor monitoring (air and tap water) as well as
ollecting information on possible exposure pathways and living
onditions via questionnaires. GerES has always been conducted in
lose co-operation with the National Health Interview and Exam-
nation Surveys (NHIES) performed by the Robert Koch-Institute
RKI). Currently study number ﬁve, GerES V, is ongoing investigat-
ng the exposures of children and youth between 3 and 17 years of
ge.
The ESB is a permanent monitoring instrument investigatingPlease cite this article in press as: Kolossa-Gehring, M.,  et al., New hum
approach to enhance relevance. Int. J. Hyg. Environ. Health (2016), htt
ime trends in both environmental and human media. It is run
ointly by UBA and research institutes with speciﬁc competencies
n relevant ﬁelds of research (e.g., sampling of human, biological,
nd abiotic material, trace analysis of pollutants, and bio bank-15 mg/l 40 mg/l
0,3 mg/l
0,5 mg/l
ing). After more than two  decades of operation the ESB provides
a continuous historical record of the state of the environment in
Germany in this period. It allows the retrospective monitoring of
pollutants to identify temporal trends and spatial load differences.
Target compounds include those which had not yet been recog-
nized as hazardous when the specimens were archived (emerging
pollutants) or which could not be analyzed with the desirable pre-
cision at that time. Thus, the ESB samples can be used to analyze
human exposure from the past using the analytical methods of the
future.
The newly developed methods for HexamollTMDINCHTM (Koch
et al., 2013; Schütze et al., 2012, 2014, 2015a,b, 2016), DPHP (Gries
et al., 2012; Leng et al., 2014; Schütze et al., 2015b) and NMP/NEP
(Koch et al., 2014) have been applied in the ESB (Schütze et al.,
2014, 2015b) and are being applied in GerES V samples. The 2-MBT-
method (Gries et al., 2015) is being applied in the current GerES
V, the HBCDD method is currently applied to ESB samples. Expo-
sure levels in none of the samples analyzed up to now exceeded
the respective HBM-I value. The method to detect MDI  (Gries and
Leng, 2013) is based on the globin fracture found in whole blood.
This procedure needs special attention and will be applied sepa-
rately to human samples. All other methods are fairly new so they
could not be integrated in ongoing studies and will be applied later
on (4-MBC, CIT/MIT, DEHTP (Lessmann et al., 2016a, 2016b), BHT,
Lysmeral (Pluym et al., 2016)).
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